ABSTRACT OBJECTIVES This study sought to evaluate whether a panel of biomarkers improved prognostication in patients with heart failure (HF) and reduced ejection fraction of ischemic origin using a systematized approach according to suggested requirements for validation of new biomarkers.
T he prognosis in patient with heart failure (HF) remains poor despite improvements in disease management. Persistent inflammation and extracellular matrix (ECM) remodeling are considered central pathogenic elements in HF progression (1) . As a result of their role in the pathogenesis of HF, circulating inflammatory and ECM markers may also be convenient, noninvasive tools for risk stratification and prognostication in these patients (2) .
We previously evaluated a range of biomarkers in
CORONA (Controlled Rosuvastatin Multinational
Trial in Heart Failure) study, comprising elderly patients with moderate-to-severe ischemic HF (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) .
Classifying these markers according to categories proposed by Braunwald (2) Although measurements of individual markers of inflammation and the EMC so far have not improved risk stratification of patients with HF in a clinically meaningful way, combinations of multiple markers might help identify subjects with a clinically significantly increased risk. The combination of multiple markers might also help select patients for individualized therapy. The idea of a multimarker approach has been around for several years, but few studies have tested the power of such models, and most of these trials included few biomarkers or examined small populations. Moreover, the lack of optimal adjustment for existing tests and the lack of internal or external validation may have biased results (17) (18) (19) .
In the present study, we used a systematized approach to assess the prognostic value of a combination of biomarkers from the CORONA trial (20) .
METHODS
For a full description of the methods, see the Online Appendix. A flow chart of the statistical approach is shown in Figure 2 . Briefly, the CORONA population was divided into 3 subgroups. Subgroup 1 had no biomarker data and was used for fitting a Cox model including routine clinical and biochemical variables as previously reported (history of diabetes, left ventricular ejection fraction, body mass index, New York Heart Association functional class, apolipoprotein B/apolipoprotein A-1 ratio, history of intermittent claudication, gender, age, heart rate, estimated glomerular filtration rate, C-reactive protein (CRP) and NT-proBNP) (21).
The Cox model was then used to calculate a prognostic score (PS) by multiplication of estimated coefficients with corresponding variables for each individual subject in the biomarker population. The Seattle heart failure score (SHFS) was calculated based on the available data (22) . Because sodium levels, lymphocyte count, and hemoglobin and uric acid acids were not available in the CORONA dataset, they were excluded from our SHFS. 
Nymo et al. Table 3 ). However, the addition of each biomarker model led to a small but significant improvement in NRI for all endpoints, except for cardiovascular (CV) mortality in model 1 ( Figure 3) . This was mainly due to patients without an event getting a lower risk score (Online Table 3 ).
COMPARISON WITH SHFS. When we used the SHFS as the base model instead of the original CORONA PS, the addition of either biomarker model markedly improved discrimination for all endpoints (Online Table 5 ). When adding NT-proBNP to the SHFS as a base model, this was no longer the case. However, NRI remained significant for all outcomes, and there Table 6 ).
EFFECT OF STATIN TREATMENT ON MARKERS OF
INFLAMMATION. In the CORONA trial, patients were randomly assigned to treatment with rosuvastatin or placebo. Therefore, we were able to investigate whether 3 months of statin treatment influenced biomarker levels in patients with HF. As shown in Online Table 7 , the relative change in biomarker levels differed between the treatment arms only for biglycan, YKL40, CXCL16, and PTX3. Biglycan and PTX3 increased more in the rosuvastatin group, whereas CXCL16 and YKL40 increased more in the placebo group. Because patients with low levels of biomarkers may have a limited potential for benefitting from the anti-inflammatory effect of statins, we also assessed treatment effects in the top 2 tertiles for each marker. In these patients, the result remained similar for PTX3, YKL40, and CXCL16, with a significant relative change in the same direction as previously observed (Online Table 8 ).
EFFECT OF STATIN TREATMENT IN DIFFERENT RISK
GROUPS. Finally, we evaluated the interaction between the PS of models 1 and 2, and the effect of rosuvastatin treatment on outcome. For all-cause mortality, there was a borderline significant interaction between rosuvastatin treatment and model 1 PS.
Patients in the lowest tertile PS had a significant effect of statin treatment, which was not the case for any of the other patients. We obtained similar results when testing interaction for model 2 PS, suggesting that patients with little inflammatory activity at the baseline of study had some effect from rosuvastatin treatment, compared with those with more inflammation ( Figure 5 ). Similar patterns were found for CV mortality and the primary endpoint, but only model 2 had a significant interaction with treatment for the primary endpoint.
DISCUSSION
Previous studies have suggested that panels of multiple biomarkers may add prognostic information to established predictive metrics in chronic HF (18, (28) (29) (30) . In this study, we were only partly able to confirm this hypothesis. Although 2 slightly different panels of biomarkers added information to the SHFS and improved NRI, even when NT-proBNP was added to the model, the clinical relevance of these markers is uncertain. Furthermore, when comparing the 2 models to the previously published CORONA model, there was only a small but significant NRI. Thus, although these data suggest that NT-proBNP is a useful prognostic biomarker in elderly patients with HF of ischemic origin, the added value of inflammatory and ECM-related biomarkers seems to be limited. Finally, our study does not support a direct anti-inflammatory effect of statin therapy in elderly patients with ischemic HF, but it does suggest that patients with a lower inflammatory burden may benefit from statin therapy.
We used 2 models to test the prognostic potential of a multimarker approach in our patients. Our selection of biomarkers from the literature (i.e., model 2) was based on the authors' judgment of biomarkers that SHFS ¼ Seattle heart failure score; SW ¼ stepwise.
Multiple Biomarkers in Chronic Heart Failure have repeatedly been suggested or have been shown to be associated with outcome in several previous studies and were available in this study (7, (23) (24) (25) (26) (27) . However, Number of observed events versus estimated number of events by time for each tertile of the prognostic risk scores of models 1 and 2 for all-cause mortality. (36) . This is especially the case with a rather homogeneous population as in this study.
However, because our main findings are negative, further decreasing the power of our models would not have changed our main conclusions. Third, we used 2 approaches to model building in this study, and both 
CONCLUSIONS
In this study, we investigated whether 2 panels of biomarkers improved the prognostic abilities of a risk score built on the CORONA population and the SHFS.
We found that although there was some improvement in discriminatory power of the models, the gains were modest and clinical relevance doubtful. However, we were not able to accomplish this using several biomarkers previously suggested in literature, reflecting different aspects of inflammation and remodeling in HF.
TRANSLATIONAL OUTLOOK: Our finding suggests that other than NT-proBNP, few biomarkers are able to add significantly to already existing risk models, even when they are put together into biomarker panels. Nymo et al.
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